Leading article: The NHS should explain

Share
Related Topics

Many breast cancer patients are delighted by the approval of Herceptin for NHS use. But the joy of this newspaper, which campaigned on their behalf, is bounded. In a minority of cases of early breast cancer, Herceptin is an effective treatment. The difficulties arise because it is only the most famous of a new family of drugs already proven effective against different forms of cancer.

Herceptin was given fast-track approval by Nice, the National Institute for Clinical Excellence. It is hard to avoid the suspicion that the procedure was accelerated partly by lobbying by popular cancer charities and by a media campaign for a fashionable cause. The Independent on Sunday played a leading role in that campaign, of which we are proud, but the Herceptin decision is very much the beginning of a victory rather than an occasion for lasting self-congratulation.

Today, we return to the question of the 20 other cancer drugs that are still waiting for Nice approval. In none of these cases does there appear to be doubt about the effectiveness or the safety of the treatment. On page 13, we report the case of Tamar Bailey, who died last week, and whose 26-year life could have been prolonged by early treatment with Avastin, a drug that shrinks tumours. But Avastin is still waiting for Nice approval, and so Tamar's primary care trust refused to pay for it.

Of course, Avastin is expensive. It costs £20,000 a year per patient. We do not argue that all treatments that could extend lives - or even all treatments that could extend the lives of young people - should be funded. If Nice decides that public money could secure better quality of lives elsewhere, that would be a decision that could be debated and challenged. What is not acceptable, though, is to use bureaucratic delay as a way of rationing by stealth.

As we have argued before, openness is the key. Everyone accepts that limited NHS resources have to be prioritised; what matters is that the process by which such priorities are set commands respect. The delay in approving the new generation of cancer drugs - which are almost certain to be approved - undermines that respect. So, too, for example, does Nice's refusal to publish the computer model used to assess the cost-effectiveness of drugs to treat Alzheimer's disease.

It may be objected that we are arguing for clinical priorities to be set by public sentimentality and media sensation. And it is certainly the case that breast cancer - and Herceptin - attracts more attention than the bowel cancer that killed Tamar or the Avastin that could have helped her. Yet the answer to that is more information and more openness, not less. The development of a new generation of expensive anti-cancer drugs requires the NHS to make some difficult trade-offs. But the public support needed to make those trade-offs can only be obtained by facing them explicitly and openly.

React Now

Latest stories from i100
iJobs Job Widget
iJobs General

Ashdown Group: Digital Marketing Executive - West London - £35,000

£28000 - £35000 per annum: Ashdown Group: A luxury fashion retailer based in W...

Ashdown Group: IT Systems Engineer - East Riding of Yorkshire

£30000 - £35000 per annum: Ashdown Group: IT Systems Engineer - East Riding of...

Recruitment Genius: IT Technician / Epos Engineer - Crayford

£15000 - £18000 per annum: Recruitment Genius: This retail and hospitality til...

Recruitment Genius: HP Technical Support Analyst

£45000 - £55000 per annum: Recruitment Genius: This rapidly expanding IT Manag...

Day In a Page

Read Next
Women come back from the fields to sell vegetables at a market in Bangui, Central African Republic  

International Women's Day: Africa's women need to believe in themselves and start leading the way

Sylvia Bongo Ondimba
 

Daily catch-up: We Are Not Syriza; and the riddle of an imitation Sphinx in China

John Rentoul
Homeless Veterans campaign: Donations hit record-breaking £1m target after £300,000 gift from Lloyds Bank

Homeless Veterans campaign

Donations hit record-breaking £1m target after huge gift from Lloyds Bank
Flight MH370 a year on: Lost without a trace – but the search goes on

Lost without a trace

But, a year on, the search continues for Flight MH370
Germany's spymasters left red-faced after thieves break into brand new secret service HQ and steal taps

Germany's spy HQ springs a leak

Thieves break into new €1.5bn complex... to steal taps
International Women's Day 2015: Celebrating the whirlwind wit of Simone de Beauvoir

Whirlwind wit of Simone de Beauvoir

Simone de Beauvoir's seminal feminist polemic, 'The Second Sex', has been published in short-form for International Women's Day
Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

Why would I want to employ someone I’d be happy to have as my boss, asks Simon Kelner
Confessions of a planespotter: With three Britons under arrest in the UAE, the perils have never been more apparent

Confessions of a planespotter

With three Britons under arrest in the UAE, the perils have never been more apparent. Sam Masters explains the appeal
Russia's gulag museum 'makes no mention' of Stalin's atrocities

Russia's gulag museum

Ministry of Culture-run site 'makes no mention' of Stalin's atrocities
The big fresh food con: Alarming truth behind the chocolate muffin that won't decay

The big fresh food con

Joanna Blythman reveals the alarming truth behind the chocolate muffin that won't decay
Virginia Ironside was my landlady: What is it like to live with an agony aunt on call 24/7?

Virginia Ironside was my landlady

Tim Willis reveals what it's like to live with an agony aunt on call 24/7
Paris Fashion Week 2015: The wit and wisdom of Manish Arora's exercise in high camp

Paris Fashion Week 2015

The wit and wisdom of Manish Arora's exercise in high camp
8 best workout DVDs

8 best workout DVDs

If your 'New Year new you' regime hasn’t lasted beyond February, why not try working out from home?
Paul Scholes column: I don't believe Jonny Evans was spitting at Papiss Cissé. It was a reflex. But what the Newcastle striker did next was horrible

Paul Scholes column

I don't believe Evans was spitting at Cissé. It was a reflex. But what the Newcastle striker did next was horrible
Miguel Layun interview: From the Azteca to Vicarage Road with a million followers

From the Azteca to Vicarage Road with a million followers

Miguel Layun is a star in Mexico where he was criticised for leaving to join Watford. But he says he sees the bigger picture
Frank Warren column: Amir Khan ready to meet winner of Floyd Mayweather v Manny Pacquiao

Khan ready to meet winner of Mayweather v Pacquiao

The Bolton fighter is unlikely to take on Kell Brook with two superstar opponents on the horizon, says Frank Warren
War with Isis: Iraq's government fights to win back Tikrit from militants - but then what?

Baghdad fights to win back Tikrit from Isis – but then what?

Patrick Cockburn reports from Kirkuk on a conflict which sectarianism has made intractable